CAJ | 학술논문

目的评价吉西他滨诱导化疗后放疗同步联合卡培他滨治疗局部进展期胰腺癌(LAPC)的安全性及疗效.方法对42例局部进展期胰腺癌用吉西他滨诱导化疗7周,每周1次,每次1 000 mg/m2,休息1周后开始放疗同步联合卡培他滨化疗,卡培他滨剂量为825 mg/m2,2次/d,5 d/周;放疗采用常规分割1.8～2.O Gy/次,中位照射剂量54 Gy(34 ～64 Gy).结果临床受益反应(CBR)20例,占47.6％;近期疗效:完全缓解(CR)2例,部分缓解(PR)8例,稳定(SD)27例,进展(PD)5例,中位生存时间10.1个月(4～36个月);1年、2年生存率分别是38.2％和18.2％.骨髓抑制1～2级20例,3级以上5例;胃肠道不良反应1～2级22例,3级以上4例.结论吉西他滨诱导化疗后再放化联合治疗局部进展期胰腺癌疗效较好,不良反应可耐受.
목적 평개길서타빈유도화료후방료동보연합잡배타빈치료국부진전기이선암(LAPC)적안전성급료효.방법 대42례국부진전기이선암용길서타빈유도화료7주,매주1차,매차1 000 mg/m2,휴식1주후개시방료동보연합잡배타빈화료,잡배타빈제량위825 mg/m2,2차/d,5 d/주;방료채용상규분할1.8～2.O Gy/차,중위조사제량54 Gy(34 ～64 Gy).결과 림상수익반응(CBR)20례,점47.6％;근기료효:완전완해(CR)2례,부분완해(PR)8례,은정(SD)27례,진전(PD)5례,중위생존시간10.1개월(4～36개월);1년、2년생존솔분별시38.2％화18.2％.골수억제1～2급20례,3급이상5례;위장도불량반응1～2급22례,3급이상4례.결론 길서타빈유도화료후재방화연합치료국부진전기이선암료효교호,불량반응가내수.
Objective To evaluate the safety and efficacy of induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapywith capecitabine in patients with locally advanced pancreatic cancer (LAPC).Methods A total of 42 patients with locally advanced pancreatic cancer were enrolled.All patients received seven cycles of induction chemotherapy of gemcitabine 1 000 mg/m2,once a week.Concurrent chemoradiotherapy began 1 week after completion of induction chemotherapy.Radiotherapy was delivered with a median dose of 54 Gy (34-64 Gy) with 1.8-2.0 Gy in a fraction.The radiotherapy was combined with capecitabin at a dosage of 825 mg/m2 twice daily,5 d/week.Results Twenty patients (47.6％) were evaluated as clinical benefit response (CBR).Two cases were observed with complete remission (CR),8 with partial remission (PR),27 with stable disease (SD),and 5 with progressive disease (PD).The median overall survival was 10.1 months (range of 4-36 months).The 1-,2-year overall survival rate was 38.2％ and 18.2％,respectively.Myelosuppression was recorded in 20 patients with grades 1-2,and 5 patients with grade 3.Twenty-two patients suffered from grade 1-2 gastrointestinal toxicities,while 4 patients suffered from grade 3.Conclusions The preliminary results showed that induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with LAPC might achieve encouraging efficacy with better tolerance.